Natural killer T-cell-mediated immunity (NKT immunity)

Natural killer T (NKT) cell-mediated immunity is a specialized immune pathway that bridges innate and adaptive defenses. NKT cells are a unique subset of T lymphocytes characterized by the expression of a semi-invariant T-cell receptor (TCR) that recognizes lipid and glycolipid antigens presented by the non-polymorphic CD1d molecule, rather than peptide-MHC complexes (Godfrey et al., Nature Reviews Immunology, 2004). Upon activation, NKT cells rapidly secrete large quantities of cytokines, such as interferon-gamma (IFN-gamma) and interleukin-4 (IL-4), which can trans-activate other immune cells including Natural Killer (NK) cells, B cells, and dendritic cells (Van Kaer et al., Frontiers in Immunology, 2013). This pathway is a significant area of clinical interest in oncology, where agonists like alpha-galactosylceramide (alpha-GalCer) are used to stimulate anti-tumor responses (Kawano et al., Science, 1997). In addition to cancer, NKT cells play critical roles in regulating autoimmune diseases and responding to infectious pathogens. However, the term "NKT cell-mediated immunity" refers to a complex physiological process involving multiple cell types and molecular interactions, and therefore is not classified as a single druggable molecular target (e.g., a specific receptor or enzyme).

Other names

NKT cell activationiNKT cell-mediated responseCD1d-restricted immune responseInvariant NKT cell response

Activation of NKT cells occurs when their semi-invariant T-cell receptor (TCR) recognizes lipid or glycolipid antigens presented by the MHC class I-like protein CD1d, leading to rapid release of Th1 and Th2 cytokines.